Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common blood pressure pill ease PTSD nightmares in veterans?

NCT ID NCT04877093

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a low dose of clonidine, a drug usually used for high blood pressure, can improve sleep and reduce PTSD symptoms in veterans. About 32 veterans with PTSD will take a flexible dose of clonidine nightly for 6 weeks. Researchers will track changes in sleep quality, PTSD severity, and mood using questionnaires and sleep diaries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clonidine pill (low dose)
What this could lead to
If it works, this could offer a simple, low-cost option to help veterans with PTSD sleep better and feel less distressed.
What could go wrong
This is a small early-phase trial with only 32 participants, so results may not apply to all veterans. Clonidine can cause side effects like low blood pressure and drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * US military veteran * Currently has PTSD diagnosis as determined by clinical diagnosing or by the PI * Screening score on PCL5 minimum of 40 (per data from previous studies36-38, a PCL5 score of 40 is roughly equivalent to a CAPS score of 30) * Scores ≥10 on PCL5 items 1-5 (intrusion) or scores ≥10 on PCL5 items 15-20 * From PCL5 questionnaire, must score the following minimum in each of the following categories: * 1x score of 2 on Questions 1-5 * 1x score of 2 on Questions 6-7 * 2x score of 2 on Questions 8-14 * 2x score of 2 on Questions 15-20 * Has score ≥3 on CAPS nightmare items B2 and E6 * Speaks and understands English * Willing to come into the clinic as programmed Exclusion Criteria: * Pregnant or breastfeeding * At Moderate or High risk of suicide based on "past month" column of the Columbia-Suicide Severity Rating Scale (CSSR-S) screen version - recent. * Has acute or unstable mental illness or any cognitive issues which the PI determines would interfere with engagement in the study (e.g., active schizophrenia, uncontrolled bipolar, history of neurocognitive impairment, history of moderate-severe traumatic brain injury) * Currently receiving exposure therapy * Recently enrolled (\<1 month) in other behavioral health therapies (exclusions made at the PI's discretion depending on therapy type and length since admission) * Urgent hypertension (BP above 160/100) or symptomatic of hypertension (having a hypertensive emergency) * Blood pressure under 100/60 or symptoms of low blood pressure (light headedness, dizziness, heart palpitations, or other symptoms as determined by clinician). * Any contraindications to taking clonidine such as: * Known hypersensitivity to clonidine * History of 2nd or 3rd degree atrioventricular block * History of sinus bradycardia * History of pheochromocytoma * History of Raynaud's phenomenon * Stage 5 Kidney disease * Recent myocardial infarction (\<6 months) * History of cerebrovascular disease or recent stoke (\<6 months) * Have used any of the following drugs in the past 30 days, unprescribed or not used as prescribed: * Heroin * Other opiates/analgesics * Barbiturates * Other sedatives/, hypnotics, or tranquilizers * Cocaine * Amphetamines * Cannabis * Hallucinogens * Inhalants * Currently have any of the following diagnoses: * Opioid use disorder * Cocaine use disorder * Alcohol use disorder * Cannabis use disorder * Sleep apnea diagnosis with verbal indication of non-adherence to treatment * Were prescribed clonidine within the last 6 months * Any α2 agonist * Catapres/Kapvay (clonidine) * Aldomet (Methyldopa) * Zanaflex (Tizanidine) * Intuniv (Guanfacine) * Lucemyra (Lofexidine) * Any α1-adrenergic antagonist * Prazosin * Terazosin * Doxazosin * Silodosin * Alfuzosin * Tamsulosin * Any opiate (e.g., buprenorphine, hydrocodone, oxycodone) * Any antipsychotic medication * Haldol (haloperidol) * Loxitane (loxapine) * Mellaril (thioridazine) * Moban (molindone) * Navane (thiothixene) * Prolixin (fluphenazine) * Serentil (mesoridazine) * Stelazine (trifluoperazine) * Trilafon (perphenazine) * Thorazine (chlorpromazine) * Abilify (aripiprazole) * Clozaril (clozapine) * Geodon (ziprasidone) * Risperdal (risperidone) * Seroquel (quetiapine) * Zyprexa (olanzapine) * Benzodiazepines * Cyproheptadine * Based on PI or study team assessment is cognitively unable to engage in the study * Has a legal guardian

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Posttraumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aurora Psychiatric Hospital

    RECRUITING

    Wauwatosa, Wisconsin, 53213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.